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Objective/background: Here, we described the clinical characteristics and outcomes of cen-
tral nervous system (CNS) infections occurring after allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) in a single institution over the previous 6 years.
Methods: Charts of 353 consecutive allogeneic transplant recipients were retrospectively
reviewed for CNS infection.
Results: A total of 17 cases of CNS infection were identified at a median of 38 days (range, 10–
1028 days) after allo-HSCT. Causative pathogens were human herpesvirus-6 (n = 6), enterococ-
cus (n = 2), staphylococcus (n = 2), streptococcus (n = 2), varicella zoster virus (n = 1), cytome-
galovirus (n = 1), John Cunningham virus (n = 1), adenovirus (n = 1), and Toxoplasma gondii
(n = 1). The cumulative incidence of CNS infection was 4.1% at 1 year and 5.5% at 5 years.
Conclusion: Multivariate analysis revealed that high-risk disease status was a risk factor for
developing CNS infection (p = .02), and that overall survival at 3 years after allo-HSCT was
33% in patients with CNS infection and 53% in those without CNS infection (p = .04).
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).al, 3-18-22
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Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) recipients are at a high risk for several central ner-
vous system (CNS) complications [1]. These complications
arise either from the primary disease for which the patient
is undergoing allo-HSCT or as a consequence of immunosup-
pressive treatments, infection, or hemorrhage that may
develop following allo-HSCT [2–4]. Although CNS infection
usually results in a dismal outcome, early diagnosis and
immediate treatment intervention may improve prognosis
[5,6]. The incidence of CNS infection ranges from 0.8% to
15% [7–14], and various causative pathogens, including bac-
teria [15], fungi [9,14], viruses [7,16–20], and protozoa
[21], have been identified, but the full spectrum of patho-
gens is not known. Multiple factors, including severe graft-
versus-host disease (GVHD) or use of high doses of an
immunosuppressive drug, such as alemtuzumab, were iden-
tified as risk factors for CNS infection. However, little is
known about the precise clinical characteristics of CNS
infection, as clinical manifestations may be difficult to dis-
tinguish from other conditions that cause neurological
symptoms [8,11–13,22,23]. This study described the clinical
course of 17 cases of CNS infection among 353 allogeneic
transplant recipients over the previous 6 years at a single
institution and reviewed their clinical outcomes.
Materials and methods
Patient demographics
We retrospectively reviewed 353 patients (210 men and 143
women; median age, 43 years; range, 16–73 years) with
various diseases who underwent allo-HSCT at our institu-
tion. Between January 2005 and December 2011, 261
patients underwent bone marrow transplantation (82
related, 179 unrelated), 48 underwent related peripheral-
blood stem cell transplantation, and 44 patients underwent
unrelated cord-blood stem cell transplantation. Clinical
characteristics of patients are summarized in Table 1.
Transplantation procedure
Preparative treatment was performed according to the pri-
mary disease and type of transplant. Generally, patients
with lymphoid malignancy were conditioned using a total
body irradiation (TBI)-containing regimen (12 Gy) that
included cyclophosphamide (CY) at 120 mg/kg with or with-
out cytarabine at 8 g/m2. Conversely, patients with myeloid
malignancy were conditioned using a non-TBI-containing
regimen that included oral busulfan (BU) at 16 mg/kg or
intravenous BU at 12.8 mg/kg and CY at 120 mg/kg. Plasma
concentrations of BU were not monitored. Patients with
severe aplastic anemia were also conditioned using a total
lymphoid irradiation-containing regimen. Reduced-
intensity conditioning regimens consisted of fludarabine-
based regimens with or without low-dose TBI. Cyclosporine
or tacrolimus plus short-term methotrexate were used for
prophylaxis. Tacrolimus was used in cases of unrelated or
mismatched transplantation. Acute and chronic GVHD werePlease cite this article in press as: Hanajiri R et al., Central nervous syst
tation ..., Hematol Oncol Stem Cell Ther (2016), http://dx.doi.org/10.101diagnosed and graded according to previously established
criteria. Tosufloxacin and fluconazole were orally adminis-
tered 14 days before allo-HSCT for prophylaxis against bac-
terial and fungal infection, respectively. For patients with a
high risk of invasive fungal infections, voriconazole was
administered instead of fluconazole. Trimethoprim and sul-
famethoxazole were administered to prevent Pneumocystis
pneumonia. Acyclovir was administered to prevent herpes
simplex virus infection until the end of administration of
immunosuppressive drugs. Cytomegalovirus (CMV) disease
monitoring using an antigenemia assay for pre-emptive gan-
ciclovir therapy was performed.
Diagnostic procedure for CNS infection and
statistical analysis
According to the standard operating procedure at our insti-
tution, symptomatic patients with an altered mental status
or convulsions, particularly those without any other identi-
fied causes of neurological dysfunction, such as hemorrhage
[4], metabolic disorder, or drug toxicity, were classified as
possibly having CNS infection. These patients immediately
underwent cerebrospinal fluid (CSF) examination with stan-
dard culturing, staining for bacterial, viral, and protozoan
pathogens, and polymerase chain reaction (PCR) testing
for human herpesvirus virus 6 (HHV-6), varicella zoster virus
(VZV), herpes simplex virus, CMV, and adenovirus. When
progressive multifocal leukoencephalopathy was consid-
ered, PCR for John Cunningham (JC) virus in the CSF was
employed.
Descriptive statistics were provided for patient-baseline
characteristics. Patient-, disease-, and transplant-related
variables were compared using Fisher’s exact test for cate-
gorical variables and the Mann-Whitney U test for continu-
ous variables. The probability of CNS infection was
calculated using the cumulative incidence-function method
and considering death without CNS infection as a competing
event. To evaluate the association between pretransplant
clinical factors and CNS infection, a logistic regression
model was used. Overall survival (OS) was calculated using
the Kaplan-Meier method and compared with the log-rank
test. OS was calculated from transplantation to death
regardless of cause. Multivariate analyses were performed
using the Cox proportional-hazards model. The following
covariates were included in the multivariate analysis: age,
sex, disease risk, stem cell source, donor type, conditioning
regimen, GVHD prophylaxis, and the development of CNS
infection. Variables with p < .10 in the univariate analyses
were subjected to multivariate analysis. Development of
CNS infection was treated as a time-dependent covariate.
All p-values were two-sided, and a p < .05 was considered
statistically significant.
Results
Clinical features of CNS infection following allo-
HSCT
The charts of 353 allo-HSCT recipients were retrospectively
reviewed for CNS infection. Table 1 summarizes the charac-em infection following allogeneic hematopoietic stem cell transplan-
6/j.hemonc.2016.08.008
Table 1 Patient characteristics.
Variable No CNS infection (n = 336) CNS infection present (n = 17) p
Age (y) Median 48 43 .51
Range 16–73 25–64
Sex Male 201 9 .62
Female 135 8
Primary disease AML 151 8 .60
ALL 70 6
MDS 48 1
CML 27 1
SAA 18 0
ML 14 0
Others 8 1
Disease riska Low 169 3 .01
High 167 14
Stem cell source BM 250 11 .09
PBSC 47 1
CB 39 5
Donor type Related 93 3 .58
Unrelated 243 14
Conditioning regimen Myeloablative 268 16 .21
Reduced intensity 68 1
GVHD prophylaxis CyA based 164 6 .33
FK based 172 11
Note. ALL = acute lymphoid leukemia; AML = acute myeloid leukemia; BM = bone marrow; CB = cord blood; CML = chronic myeloid leu-
kemia; CNS = central nervous system; CyA = cyclosporine; FK = tacrolimus; GVHD = graft-versus-host disease; MDS = myelodysplastic
syndrome; ML = malignant lymphoma; PBSC = peripheral blood stem cell; SAA = severe aplastic anemia.
a Disease risk was classified into two categories: high risk included acute leukemia not in remission, myelodysplastic syndrome with
excess blast count, or chronic myelomonocytic leukemia and the others were classified as low risk.
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Figure 1 Cumulative incidence of the development of CNS
infection following allo-HSCT. The incidences for patients with
high-risk-disease status versus those with low-risk-disease
status are shown. Note. Allo-HSCT = allogeneic hematopoietic
stem cell transplantation; CNS = central nervous system.
CNS infection following allogeneic HSCT 3teristics of these 353 patients. Of these patients, 17 eventu-
ally developed CNS infection at a median of 38 days (range,
10–1028 days) after allo-HSCT. The median age at the time
of CNS infection was 43 years (range, 25–64 years), and nine
patients were men (53%). Most patients underwent unre-
lated HSCT with a myeloablative-conditioning regimen
(Table 1). No patients with CNS infections received anti-
thymocyte globulin as a conditioning regimen. The cumula-
tive incidence of CNS infection was 4.1% at 1 year and 5.5%
at 5 years after allo-HSCT. High-risk-disease status was a
significant clinical factor for CNS infection according to uni-
variate analysis (p = .01), and this factor remained signifi-
cant according to multivariate analysis (relative
risk = 4.56; 95% confidence interval, 1.28–16.2; p = .02).
The 5-year cumulative incidence of CNS infection in patients
with high-risk-disease status was 8.8%, whereas the inci-
dence was 1.8% in patients with low-risk-disease status
(Fig. 1).
Of the 17 patients who developed CNS infection (Table 2),
the types of CNS infection were meningitis (n = 5),
encephalitis (n = 3), meningoencephalitis (n = 6), brain
abscess (n = 2), and progressive multifocal leukoen-
cephalopathy (n = 1). The causative pathogens were HHV-6
(n = 6), enterococcus (n = 2), staphylococcus (n = 2), strep-
tococcus (n = 2), VZV (n = 1), CMV (n = 1), JC virus (n = 1),Please cite this article in press as: Hanajiri R et al., Central nervous system infection following allogeneic hematopoietic stem cell transplan-
tation ..., Hematol Oncol Stem Cell Ther (2016), http://dx.doi.org/10.1016/j.hemonc.2016.08.008
Table 2 Clinical characteristics and outcomes of CNS infection.
Case Age (y) Sex Primary disease Stem cell source Conditioning GVHD prophylaxis Clinical findings
Type of CNS infection Causative pathogen Onset (day after transplantation) Prior steroid use Altered mental status Convulsions
1 55 F CML UBM CA+CY+TBI CyA+sMTX Meningoencephalitis HHV-6 Day 49 Yes Yes No
2 51 F MDS RBM BU+CY FK+sMTX Meningoencephalitis HHV-6 Day 36 Yes Yes No
3 42 M ATL CB CA+CY+TBI FK+sMTX Meningoencephalitis HHV-6 Day 27 No Yes No
4 48 M AML CB CA+CY+TBI FK+sMTX Meningoencephalitis HHV-6 Day 25 No Yes No
5 64 M ALL UBM Flu+Mel+TBI FK+sMTX Meningoencephalitis HHV-6 Day 19 No Yes No
6 34 M AML UBM BU+CY FK+sMTX Meningoencephalitis HHV-6 Day 21 Yes Yes Yes
7 34 F ALL UBM CY+TBI FK+sMTX Meningitis VZV Day 509 Yes No No
8 58 M ALL UBM CA+CY+TBI FK+sMTX Encephalitis CMV Day 38 Yes Yes No
9 55 F AML UBM BU+CY FK+sMTX PML JCV Day 1028 No Yes No
10 39 M ALL RPB CY+TBI CyA+sMTX Encephalitis ADV Day 121 Yes Yes No
11 58 F AML RBM BU+CY FK+sMTX Encephalitis Toxoplasma Day 101 Yes Yes No
12 37 M ALL CB CA+CY+TBI FK+sMTX Meningitis Enterococcus Day 13 Yes No No
13 45 F AML CB CA+CY+TBI CyA+sMTX Meningitis Enterococcus Day 11 No No No
14 50 F AML UBM BU+CY FK+sMTX Brain abscess S capitis Day 843 No Yes No
15 55 F ALL UBM CA+CY+TBI CyA+sMTX Brain abscess S capitis Day 150 Yes Yes No
16 25 M AML RBM BU+CY CyA+sMTX Meningitis S pneumonia Day 307 Yes Yes No
17 31 M AML CB CA+CY+TBI CyA+MMF Meningitis S haemolyticus Day 10 No Yes No
Case Laboratory findings Radiologic findings Treatment outcomes
WBC (/lL) Platelets (/lL) CSF Brain CT Brain MRI (abnormal lesions) Treatment modality Response Survival status at the last follow-up
(days after onset of CNS infection)
Cause of death
Cell count (mm3) Protein (mg/dL)
1 3600 2.2 3 57.0 Normal Left medial temporal lobe DHPG? Foscarnet Improved Dead (234) Unknown
2 1100 2.2 41 59.0 Normal Medial temporal lobe DHPG? Foscarnet Improved but persistent memory impairment Alive (1737+) NA
3 2600 1.9 0 37.9 Normal Normal DHPG? Foscarnet No response Dead (78) Sepsis
4 50 0.8 0 0.0 ND Normal Foscarnet Improved but persistent disorientation Dead (81) Disease progression
5 2300 2.6 1 76.5 ND Normal Foscarnet Improved Dead (41) Pneumonia
6 3900 1.5 3 23.0 Normal Medial temporal lobe Foscarnet Persistent disturbance of consciousness Dead (141) Pneumonia
7 8300 11.0 283 125.4 Normal Normal ACV Improved Alive (1055+) NA
8 6100 2.6 364 362.0 ND ND Foscarnet Improved with exacerbation Dead (41) CNS infection
9 6100 15.2 2 26.0 ND Cerebellum Mefloquine No response Dead (107) CNS infection
10 2800 3.2 2 216.0 ND ND ND NA Dead (11) CNS infection
11 700 4.2 1 63.0 Normal Basal ganglia ST No response Dead (10) CNS infection
12 10 0.6 4 40.1 Normal ND VCM? LZD No response Dead (14) CNS infection
13 20 2.6 0 20.4 Normal Meningeal enhancement VCM? LZD Improved but persistent memory impairment Alive (1258+) NA
14 6900 6.0 ND ND ND Frontal lobe MEPM+VCM No response Alive (16+) NA
15 5100 2.3 61 138.3 ND Right frontal lobe VCM Improved Alive (475+) NA
16 12,600 12.3 4208 62.4 Normal Sinusitis CTRX+VCM Improved Alive (1284+) NA
17 30 1.1 7 41.0 ND Normal VCM No response Dead (15) CNS infection
Note. ACV = acyclovir; ADV = adenovirus; ALL = acute lymphoid leukemia; AML = acute myeloid leukemia; ATL = adult T cell leukemia; BU = busulfan; CA = cytarabine; CB = cord blood;
CML = chronic myeloid leukemia; CMV = cytomegalovirus; CNS = central nervous system; CSF = cerebrospinal fluid; CT = computed tomography; CTRX = ceftriaxone; CY = cyclophosphamide;
CyA = cyclosporine; DHPG = ganciclovir; F = female; FK = tacrolimus; GVHD = graft-versus-host disease; HHV-6 = human herpesvirus 6; JCV = John Cunningham virus; LZD = linezolid;
M = male; MDS = myelodysplastic syndrome; MEPM = meropenem; MMF = mycophenolate mofetil; MRI = magnetic resonance imaging; NA = not applicable; ND = not done; PML = progressive
multifocal leukoencephalopathy; RBM = related bone marrow; RPB = related peripheral blood stem cell; sMTX = short-term methotrexate; ST = trimethoprim/sulfamethoxazole; TBI = total
body irradiation; UBM = unrelated bone marrow; VCM = vancomycin; VZV = varicella zoster virus; WBC = white blood cell; S capitis = Staphylococcus capitis; S haemolyticus = Staphylococcus
haemolyticus; S pneumonia = Streptococcus pneumoniae.
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Figure 2 OS following allo-HSCT for patients with and
without CNS infection. Note. Allo-HSCT = allogeneic hematopoi-
etic stem cell transplantation; CNS = central nervous system;
OS = overall survival.
CNS infection following allogeneic HSCT 5adenovirus (n = 1), and Toxoplasma gondii (n = 1). All 10
cases of viral infections were diagnosed with a PCR assay
of CSF, and the six cases of bacterial infections were diag-
nosed with bacterial culture of CSF or abscess. Toxoplasmo-
sis was diagnosed following a brain autopsy. At the onset of
CNS infection, 10 patients (59%) were receiving steroids for
GVHD treatment. Fourteen patients (82%) developed an
altered mental status, and one patient developed convul-
sions. Seven patients (41%) showed fever (>38 C), and high
blood pressure (systolic blood pressure > 160 mmHg or dias-
tolic blood pressure > 90 mmHg) was observed in five
patients. Engraftment had been achieved in 12 patients
(71%) at the onset of CNS infection. Lumbar puncture was
performed in 16 patients, and cell counts were elevated in
five of these patients (31%). Median cell counts were
3 mm3 (range, 0–4208 mm3), and protein levels were ele-
vated in nine patients (53%). Cranial computed tomography
was performed in nine patients, but the results were essen-
tially normal in all of the patients. Magnetic resonance
imaging was performed in 14 patients, and nine patients
(64%) displayed abnormal findings (Table 2). Abnormalities
in the medial temporal lobe were observed in three of the
six patients with HHV-6 infection. The median onset time
of HHV-6 infection seemed to be earlier as compared with
that of other CNS infections, although the difference was
not statistically significant (26 days vs. 121 days; p = .18).
(see Table 3)
Treatment and outcome
A summary of treatments for CNS infection is presented in
Table 2. The probability of an overall response was 53%;
however, minor neurological symptoms remained in four
patients (data not shown). Foscarnet was administered to
all six patients with HHV-6 infection. Of these patients,
two improved completely, but the remaining four improved
with minor neurological symptoms or did not respond to the
treatment. We were able to analyze sequential HHV-6 PCR
values in three patients (Cases 1, 2, and 6), and in each
patient, HHV-6 copy number in CSF decreased after initia-
tion of foscarnet treatment (Case 1: HHV-6 PCR positive
to negative; Case 2: 3000 copies/mL to undetectable; and
Case 6: from 77,000 copies/mL to 150 copies/mL). For VZV
meningitis (Case 7), CMV encephalitis (Case 8), and progres-
sive multifocal leukoencephalopathy due to JC virus (Case
9), acyclovir, foscarnet, and mefloquine were administered,
respectively. The patient with toxoplasmosis (Case 11)
developed respiratory failure with diffuse bilateral infil-
trates at the onset. Pneumocystis pneumonia was initially
suspected, and, therefore, sulfamethoxazole-trimethoprim
was administered. At autopsy, the brain of the patient
showed widespread necrotizing tissue in the caudateTable 3 Multivariate analysis of adverse factors for overall surv
Factors RR
CNS infection (yes vs. no) 2.27
Disease risk (high vs. low) 2.57
Donor type (unrelated vs. related) 1.86
Note. CI = confidence interval; CNS = central nervous system; RR = rela
Please cite this article in press as: Hanajiri R et al., Central nervous syst
tation ..., Hematol Oncol Stem Cell Ther (2016), http://dx.doi.org/10.101nucleus, basal ganglia, thalamus, hippocampus, cerebrum,
cerebellum, midbrain, and pons, with abundant Toxoplasma
gondii cysts and free tachyzoites (trophozoites). Toxo-
plasma cysts were also visualized in the lung, thyroid, stom-
ach, uterus, ovary, and peritoneum. For the six patients
with bacterial meningitis, a bulk dose of antibiotics was
intravenously administered. Two patients responded com-
pletely, and one patient improved with persistent memory
impairment.
As shown in Fig. 2, OS in patients with CNS infection was
significantly inferior to that observed in those without CNS
infection (33% vs. 53% at 3 years; p = .04). Only six patients
were alive at a median follow-up of 39 months (range, 1–58
months) after diagnosis of CNS infection. The median OS
after the onset of CNS infection as determined using the
Kaplan-Meier method was only 107 days. Only four patients
simultaneously developed systemic infection documented
by blood culture or autopsy. Causative pathogens for sys-
temic infection were enterococcus (Cases 12 and 13), Strep-
tococcus pneumoniae (Case 16), and Toxoplasma gondii
(Case 11). The main cause of death was CNS infection in
six patients, other infections in three patients, and disease
progression in two patients (Table 2).
Discussion
In our series, 4.8% of allo-HSCT recipients developed CNS
infection at a median of 38 days after transplantation.
The incidence of CNS infection varies from 0.8% to 15%ival.
95% CI p
1.20–4.28 .01
1.80–3.68 <.01
1.24–2.77 <.01
tive risk.
em infection following allogeneic hematopoietic stem cell transplan-
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6 R. Hanajiri et al.[7–14], with the discrepancy in these incidences possibly
due to differences in study design, patient population of
the studies, definition of CNS infection, or prophylactic
strategies for infections. In a retrospective study of 2628
patients undergoing allo-HSCT, Schmidt-Hieber et al. [7]
reported that the incidence of viral encephalitis was 1.2%,
a result comparable with ours. Regarding the risk factors
for CNS infection, in a retrospective study of 655 patients
who underwent allogeneic or autologous transplantation,
Maschke et al. [11] revealed that severe GVHD or the use
of high doses of immunosuppressive drugs may induce a risk
for developing toxoplasma encephalitis. In our study, a high-
risk-disease status was an independent risk factor for CNS
infection, which may be attributed to the immunosuppres-
sive status due to multiple courses of intensive chemother-
apy before transplantation. The prognosis of patients with
CNS infection after allo-HSCT is extremely poor. Schmidt-
Hieber et al. [7] reported that the median survival after
the onset of viral encephalitis was only 94 days, with higher
mortality in patients with rather than those without viral
encephalitis. In our study, the median OS after the onset
of CNS infection was 107 days, and OS at 3 years after
allo-HSCT was 33%, similar to a report by Maschke et al.
[11] Although in four cases it appeared that CNS disease
was secondary to a systemic infection, most of the patients
developed sole manifestation of the pathogen. Therefore,
the worse 3-year OS observed among patients with CNS
infections was a direct consequence of CNS infection.
Among our 17 cases of CNS infection, viruses accounted
for 58%, bacteria for 36%, and protozoa for 6%; however,
no fungal CNS infection was observed in our series. Maschke
et al. [11] reported that cerebral aspergillosis was the sec-
ond most common CNS infection post-transplantation. In
another autopsy series of 180 transplant recipients, 27
patients had an infection in the brain parenchyma, and fungi
were isolated in up to 60% of their cases [10]. The discrep-
ancy in the causative pathogens may be due to differences
in prophylactic strategies or the choice of diagnostic modal-
ities for CNS infection.
Regarding HHV-6 meningoencephalitis, although all six
patients received foscarnet relatively early in their clinical
courses, only two showed good cognitive recovery, and four
continued to have memory impairment or disorientation.
Moreover, most patients died during follow-up, although
no patients died of HHV-6 meningoencephalitis, similar to
previous reports showing that >50% of patients with HHV-6
meningoencephalitis died of encephalitis-unrelated causes,
such as GVHD and other infections [24,25]. Although inci-
dental positivity of CSF PCR for HHV-6 in chromosomally
integrated HHV-6 (ciHHV-6) patients with CSF pleocytosis
may result in erroneous diagnosis of HHV-6 meningoen-
cephalitis [26], considering that all six patients developed
typical clinical features of HHV-6 meningoencephalitis, the
possibility of misdiagnosis due to ciHHV-6 seems unlikely.
We also focused on the initial clinical findings of CNS
infection; however, not surprisingly, we found no specific
features in our series. Although most patients presented
with altered mental status as the initial manifestation,
<50% of patients developed fever (>38C), and convulsions
were observed in only one patient with HHV-6 infection.
In a retrospective study of 1461 allo-HSCT cases, CNS infec-
tion was documented in 14 (17.7%) out of 79 patients withPlease cite this article in press as: Hanajiri R et al., Central nervous syst
tation ..., Hematol Oncol Stem Cell Ther (2016), http://dx.doi.org/10.101convulsions [27]. Thus, the initial manifestation of CNS
infection may be very similar to that of other disorders,
such as cerebrovascular disease, metabolic disorder, and
drug toxicity [5,10,23,25]. Therefore, a positive diagnostic
strategy, including PCR testing of CSF for virus infection
and magnetic resonance imaging rather than computer
tomography, may be needed to reach an accurate diagnosis,
although not all positive cultures or PCR-testing results are
reflective of the true infection and results should be inter-
preted with caution.
This study had a limitation due to its retrospective nat-
ure. Additionally, we may have overlooked some patients
with CNS infection, despite detailed database analysis and
extensive chart review. Nevertheless, our aim was to review
the clinical outcomes of 353 allogeneic transplant patients
after CNS infection over a 6-year period and to provide use-
ful insights into this phenomenon.
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